4D Molecular Therapeutics, Inc.
FDMT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$160,868 | -$100,837 | -$107,494 | -$71,317 |
| Dep. & Amort. | $6,705 | $5,749 | $3,880 | $3,020 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $26,116 | $19,665 | $0 | $13,799 |
| Change in WC | $537 | $630 | -$1,336 | -$15,534 |
| Other Non-Cash | -$7,075 | -$999 | $18,265 | $898 |
| Operating Cash Flow | -$134,585 | -$75,792 | -$86,685 | -$69,134 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$3,786 | -$2,771 | -$11,536 | -$9,110 |
| Net Acquisitions | $0 | $0 | $0 | $9,110 |
| Inv. Purchases | -$467,652 | -$54,802 | -$153,313 | -$168,570 |
| Inv. Sales/Matur. | $169,001 | $0 | $147,799 | $5,000 |
| Other Inv. Act. | $0 | $173,290 | $0 | -$9,110 |
| Investing Cash Flow | -$302,437 | $115,717 | -$17,050 | -$172,680 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $331,412 | $148,344 | $3,085 | $114,296 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $5,838 | $8,488 | $0 | $3,793 |
| Financing Cash Flow | $337,250 | $156,832 | $3,085 | $118,089 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | -$99,772 | $196,757 | -$100,650 | -$123,725 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $249,108 | $52,351 | $153,001 | $276,726 |
| End Cash | $149,336 | $249,108 | $52,351 | $153,001 |
| Free Cash Flow | -$138,371 | -$78,563 | -$98,221 | -$78,244 |